Latest revenue
$2.7K
as of 2026-03-31
Latest net income
$-1.8M
as of 2026-03-31
Net margin
-66722.3%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $4.8M
- Enterprise value
- $4.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $7.91
- 52-wk low
- $0.97
- Beta
- —
- Shares out
- 3.0M
5-year trend
What this company does
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis provide information that Cardio’s management believes is relevant to an assessment and understanding of Cardio’s results of operations and financial condition. You should read the following discussion and analysis of Cardio’s results of operations and financial condition together with its unaudited condensed consolidated financial statements and related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q, and its audited consolidated financial statements and related notes to those statements included in the Company’s 2025 Annual…
AI summary unavailable — showing raw filing excerpt
Generated from CDIO's filing dated 2026-05-15
Key risks
ITEM 1A. RISK FACTORS There have been no material changes to the risk factors previously described in Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. These risk factors, collectively, describe some of the assumptions, risks, uncertainties and other factors that could adversely affect our business or that could otherwise result in changes that differ materially from our expectations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC, including as set forth below. Additional risks and uncertainties not currently known to us or that we currently deem to be…
AI summary unavailable — showing raw filing excerpt
Generated from CDIO's filing dated 2026-05-15
Profitability
Operating margin
-43737.5%
82.4%Net margin
-43832.5%
82.4%Return on equity
-93.2%
6.2%Return on assets
-83.7%
5.9%Leverage
Debt / equity
0.11×
2.8%Debt / assets
10.2%
2.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $2.7K | +185.1% | $-1.8M | -9.4% | -66722.3% |
Q4 2025 2025-12-31 | $3.6K | -21.2% | $-1.5M | +3.6% | -41219.9% |
Q3 2025 2025-09-30 | $2.9K | -56.6% | $-1.7M | -21.4% | -60053.8% |
Q2 2025 2025-06-30 | $7.5K | -5.0% | $-1.7M | -30.7% | -22517.7% |
Q1 2025 2025-03-31 | $940 | -94.1% | $-1.6M | +60.7% | -173943.0% |
Q4 2024 2024-12-31 | $4.5K | — | $-1.5M | — | -33672.6% |
Q3 2024 2024-09-30 | $6.6K | -34.4% | $-1.4M | +26.9% | -21467.6% |
Q2 2024 2024-06-30 | $7.9K | +356.2% | $-1.3M | +68.0% | -16365.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on CDIO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CDIO
Institutional value
$292.8K
Total shares held
150.2K
Distinct holders
9
-6 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | 81.3K | $158.5K | — | New |
| 2 | BlackRock, Inc. | 34.7K | $67.7K | -859 (-2.4%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 20.2K | $39.3K | — | New |
| 4 | UBS Group AG | 9.9K | $19.3K | +9.0K (+941.9%) | Added |
| 5 | VANGUARD FIDUCIARY TRUST CO | 4.0K | $7.7K | — | New |
| 6 | WOLVERINE ASSET MANAGEMENT LLC | 104 | $203 | +0 (+0.0%) | No change |
| 7 | SHP Wealth Management | 16 | $31 | +0 (+0.0%) | No change |
| 8 | SBI Securities Co., Ltd. | 10 | $20 | -16 (-61.5%) | Trimmed |
| 9 | CITIGROUP INC | 1 | $2 | -25 (-96.2%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CDIO's latest filing finishes processing.